checkAd

     124  0 Kommentare Zealand Pharma to participate in upcoming investor conferences

    Company announcement – No. 17 / 2020

    Zealand Pharma to participate in upcoming investor conferences

    Copenhagen, DK and Boston, MA, U.S. March 25, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in April:

    Guggenheim Virtual Healthcare Talks - Genomic Medicines & Rare Disease
    Date: Thursday, April 1, 2021
     
    20th Annual Virtual Needham Healthcare Conference  
    Date: Monday, April 12, 2021  
    Presentation: 11:45 a.m. ET/ 4:45 p.m. CET


    A live webcast of the Needham event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

    # # #

    About Zealand Pharma A/S
    Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

    For further information, please contact:

    Zealand Pharma Investor Relations
    Claudia Styslinger
    Argot Partners
    investors@zealandpharma.com

    Zealand Pharma Media Relations
    David Rosen
    Argot Partners
    media@zealandpharma.com





    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Zealand Pharma to participate in upcoming investor conferences Company announcement – No. 17 / 2020 Zealand Pharma to participate in upcoming investor conferences Copenhagen, DK and Boston, MA, U.S. March 25, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused …

    Schreibe Deinen Kommentar

    Disclaimer